Press Releases.
“BIOCAPTIVA to conduct ex-vivo study to evaluate the potential of the BioCaptis device to capture cell free DNA to improve pleural disease diagnosis “
- 12 October 2023
“BIOCAPTIVA announces oversubscribed £2.1 million additional seed financing to complete first in human trial with the BioCaptis”
- 01 June 2022
“BIOCAPTIVA Appoints Alison Williamson as Chief Financial Officer and Board Director “
- 13 April 2022
“BIOCAPTIVA Provides Update and Remains on Track to Transform the Liquid Biopsy Market for Cancer Management”
- 05 January 2022
“BIOCAPTIVA Appoints Frank Armstrong and Stephen Little to its Board of Directors”
– 21 April 2021
“BIOCAPTIVA spins out from the University of Edinburgh with proprietary cfDNA capture technology to revolutionise liquid biopsy testing for cancer management”
- 1 April 2021
BIOCAPTIVA in the Press.
“A novel next generation “liquid biopsy” technology device”
– The National, 2021
“A spin-out from the University of Edinburgh has raised £1million to develop a new device that could “revolutionise” the early diagnosis and monitoring of difficult to detect cancers, such as kidney, thyroid and brain cancer.
– The Herald, 2021
“a medical device that captures circulating free DNA from the blood of patients in much greater quantities than the current standard of a single blood draw can, overcoming a significant current limitation of cancer liquid biopsy testing.”
– The Scotsman, 2021